Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Cancer-Drug-Screen

Financiado

High throughput drug screening for identifying personalized cancer treatments ta...

High throughput drug screening for identifying personalized cancer treatments tailored to the particular mutations of the patient s tumor Cancer is caused by a series of genetic alterations that confer an advantage to cancer cells, leading to uncontrolled growth. However, each tumor exhibits distinct molecular changes, making each patient’s malignancy unique. Hence,... ver más

30/09/2016

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-09-30

ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

2 Participantes

WEIZMANN

150.00K€ | Lider

COFLUSA

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-74072-JIN DRIVERMAP: ESTIMANDO LA RELEVANCIA DE LAS MUTACIONES ONCOGEN... 205K€ Cerrado

CNS2023-143848 Cáncer 200K€ Cerrado

SAF2015-66084-R AVANZANDO EN LA INTERPRETACION DE GENOMAS DE TUMORES PARA ME... 290K€ Cerrado

CPP2021-009037 DESARROLLO DE TEST DIAGNÓSTICOS BASADOS EN DNA PARA PERSONAL... 474K€ Cerrado

CPP2021-008602 Potenciando el tratamiento personalizado del cáncer colorrec... 874K€ Cerrado

PDC2022-133583-I00 MONITORIZACION DE LA APOPTOSIS EN TIEMPO REAL PARA LA MEDICI... 132K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-03-19
Fecha Fin: 2016-09-30

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Cancer is caused by a series of genetic alterations that confer an advantage to cancer cells, leading to uncontrolled growth. However, each tumor exhibits distinct molecular changes, making each patient’s malignancy unique. Hence, in the personalized medicine era, cancer treatment aims to tailor the most suitable treatment for each patient according to his/her genetic background, tumor acquired mutations and clinical indications. The p53 tumor suppressor is the most frequently mutated gene in human cancers, with thousands of different tumor-associated mutations reported. Many such cancer-associated mutations in p53 lead to loss of its tumor suppressive activity and in some cases, to gain of new oncogenic functions, resulting in tumor recurrence and enhanced patient mortality. Importantly, tumors with different p53 mutations exhibit specific cancerous phenotypes and do not respond to particular treatments. Based on our ERC-funded breakthrough technology, where we made a library of ~10,000 distinct p53 variants, and based on our strong IPR offering and competitive advantages, here we propose to develop three products for determining which treatment (or combination) would be most effective for treating a patient’s tumor according to his specific p53 sequence, reducing excruciating side effects and improving treatment outcomes: 1) Offering patients/physicians a list of treatments ranked by their efficacy in treating cells of similar origin and p53 mutations to those present in the patient’s tumor, allowing them to make more informed treatment decisions. 2) Offering companies in the personalized cancer treatment field access to our existing proprietary data regarding treatment efficacies towards p53 genetic variants. 3) A service to drug developing companies that applies our technology for testing the efficacy of a client-supplied drug of interest over all ~10,000 p53 mutations in our library in a cell-line of choice.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores